Welcome to LookChem.com Sign In|Join Free
  • or
1H-Imidazole, 1-ethyl-4,5-bis(4-methoxyphenyl)- is a complex organic compound with the molecular formula C18H20N2O2. It is a derivative of imidazole, a heterocyclic aromatic organic compound with a five-membered ring containing two nitrogen atoms. This specific compound features an ethyl group attached to the imidazole ring at the 1-position, and two 4-methoxyphenyl groups attached at the 4 and 5 positions. The presence of methoxy groups (-OCH3) on the phenyl rings contributes to the compound's lipophilicity and potential biological activity. This chemical is primarily used in research and development, particularly in the synthesis of pharmaceuticals and other bioactive molecules, due to its unique structure and properties.

3363-51-7

Post Buying Request

3363-51-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3363-51-7 Usage

Chemical Family

The compound belongs to the family of imidazoles, which are heterocyclic organic compounds.

Structure

It is a derivative of imidazole with an ethyl group and two 4-methoxyphenyl groups attached to the 4 and 5 carbon atoms.

Biological Activities

The compound has potential biological activities, including antifungal, antibacterial, and antiprotozoal properties.

Industrial Applications

It can be used as a building block in organic synthesis to create more complex molecules for various industrial applications.

Potential Uses

The compound may have potential uses in material science and as a catalyst in chemical reactions.

Pharmaceutical and Agrochemical Applications

Due to its biological activities, the compound has potential applications in pharmaceuticals and agrochemicals.

Check Digit Verification of cas no

The CAS Registry Mumber 3363-51-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,3,6 and 3 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 3363-51:
(6*3)+(5*3)+(4*6)+(3*3)+(2*5)+(1*1)=77
77 % 10 = 7
So 3363-51-7 is a valid CAS Registry Number.

3363-51-7Relevant academic research and scientific papers

Synthesis and in vitro anticancer activities of selenium N-heterocyclic carbene compounds

Huang, Sheng,Sheng, Xinyu,Bian, Mianli,Yang, Zhibin,Lu, Yunlong,Liu, Wukun

, p. 435 - 444 (2021/07/14)

Fourteen novel selenium N-heterocyclic carbene (Se-NHC) compounds derived from 4,5-diarylimidazole were designed, synthesized, and evaluated as antiproliferative agents. Most of them were more effective toward A2780 ovarian cancer cells than HepG2 hepatocellular carcinoma cells. Among them, the most active compound 2b was about fourfold more active than the positive control ebselen against A2780 cells. In addition, this compound displayed twofold higher cytotoxicity to A2780 cells than to IOSE80 normal ovarian epithelial cells. Further studies revealed that 2b could induce reactive oxygen species production, damage mitochondrial membrane potential, block the cells in the G0/G1 phase, and finally promote A2780 cell apoptosis.

Application of N-heterocyclic carbene selenium-gold compound in preparation of carbapenem-resistant acinetobacter baumannii drug

-

Paragraph 0024; 0029-0031; 0034; 0038, (2021/07/21)

The invention discloses application of an N-heterocyclic carbene selenium-gold compound in preparation of a novel antibacterial drug resistant to carbapenem acinetobacter baumannii infection, and belongs to the technical field of drug preparation. According to the N-heterocyclic carbene selenium-gold compound, selenium-containing imidazole N-heterocyclic carbene selenium is used for replacing a thiosaccharide ligand in a gold nofen structure; the reaction activity of Au-Se in the N-heterocyclic carbene selenium-gold compound is higher than that of an Au-S bond, so that the Au-S bond in a Jinnofen structure can be prevented from being easily damaged by reducing mercaptan to a certain extent; and toxic and side effects are caused by metabolism before reaching a target spot. In-vitro antibacterial activity shows that IC50 of the compounds H7 and H8 in inhibition of carbapenem-resistant acinetobacter baumannii is 3.34 mu M and 4.67 mu M, MIC of the same are both 10 mu M, and MBC of the same are both 20 mu M. The animal in-vivo administration also shows a good anti-drug-resistant bacterium effect, which proves that the compound can significantly prolong the survival time of mice infected by drug-resistant bacteria, and has important practical application value.

A new rhodium(I) NHC complex inhibits TrxR: In vitro cytotoxicity and in vivo hepatocellular carcinoma suppression

Fan, Rong,Bian, Mianli,Hu, Lihong,Liu, Wukun

, (2019/10/01)

Thioredoxin reductase (TrxR) is often overexpressed in different types of cancer cells including hepatocellular carcinoma (HCC) cells and regarded as a target with great promise for anticancer drug research and development. Here, we have synthesized and characterized nine new designed rhodium(I) N-heterocyclic carbene (NHC) complexes. All of them were effective towards cancer cells, especially complex 1e was more active than cisplatin and manifested strong antiproliferative activity against HCC cells. In vivo anticancer studies showed that 1e significantly repressed tumor growth in an HCC nude mouse model and ameliorated liver lesions in a chronic HCC model caused by CCl4. Notably, a mechanistic study revealed that 1e can strongly inhibit TrxR system both in vitro and in vivo. Furthermore, 1e promoted intracellular ROS accumulation, damaged mitochondrial membrane potential, promoted cancer cell apoptosis and blocked the cells in the G1 phase.

Specific group modified N1 and N3 substituted 4,5-diaryl imidazole ring carbine rhodium complex and preparation method and application thereof

-

, (2019/12/25)

The invention discloses a specific group modified N1 and N3 substituted 4,5-diaryl imidazole ring carbine rhodium complex and a preparation method and application thereof. The structure of the rhodiumcomplex is shown as the formula II (please see the specification for the formula II), wherein R1 is selected from halogen, and C1-4 alkoxy or aryl, R2 is selected from C1-4 alkyl, and substituted ornon-substituted C1-4 alkyl, and a substituent group is selected from an aromatic ring or C3-6 cycloalkyl. In-vivo experiments show that the tumor growth inhibition rate of the rhodium complex under the dosage of 10 mg.kg can reach 45%, and the rhodium complex has the very high tumor growth inhibition capability and high safety, and has good application prospects in the aspect of developing novel non-platinum efficient anticancer drugs.

Synthesis, antitumor, and antibacterial activity of Bis[4,5-diarylimidazol- 2-ylidene]methane derivatives

Liu, Wukun,Chen, Xiaohua,Gust, Ronald

, p. 557 - 564 (2012/08/27)

Cationic [bis(1,3-diethyl-4,5-diarylimidazol-2-ylidene)]Au(I) bromide complexes have demonstrated considerable potential as new antitumor agents. In order to investigate whether the gold is crucial for the antitumor activity, the imidazole ligands were connected by a methylene bridge. Biological evaluation revealed that bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]methane compounds exhibited growth inhibition effects against mammary (MCF-7 and MDA-MB 231) and colon (HT-29) carcinoma cell lines. In comparison with gold complexes, the methylene derivatives showed drastically reduced cell growth inhibitory properties. However, the growth of bacteria was significantly inhibited by bis[1,3-diethyl-4,5-bis(4-methoxyphenyl)imidazol-2-ylidene]methane dibromide (4) and opens a new application of this compound type. To investigate whether the gold in cationic [bis(1,3-diethyl-4,5-diarylimidazol-2-ylidene)]Au(I) bromide complexes is crucial for their antitumor activity, the imidazole ligands were connected by a methylene bridge. In comparison with the gold complexes, the methylene derivatives showed drastically reduced cell growth inhibitory properties. However, the growth of bacteria was significantly inhibited by bis[1,3-diethyl-4,5-bis(4-methoxyphenyl)imidazol-2-ylidene]methane dibromide (4), opening a new application of this compound type. Copyright

Synthesis and biological studies of silver N-heterocyclic carbene complexes derived from 4,5-diarylimidazole

Liu, Wukun,Bensdorf, Kerstin,Hagenbach, Adelheid,Abram, Ulrich,Niu, Ben,Mariappan, Aruljothi,Gust, Ronald

, p. 5927 - 5934 (2012/01/02)

A novel class of silver N-heterocyclic carbene complexes (5a-f) were synthesized in high yield by reacting silver(I) oxide with 4,5-diarylimidazolium halides (4a-f). The complexes were characterized using NMR and IR spectroscopy. The structure was confirmed on the example of bromo[1,3-diethyl-4,5-bis(4- fluorophenyl)imidazol-2-ylidene]silver(I) (5c) by crystal structure analysis. The X-ray structure indicated a three-dimensional coordination polymer with a repeating unit consisting of a Ccarben-Ag2-Br 2-Ccarben cluster. Pharmacological investigations revealed that all silver complexes possessed growth inhibitory effects against breast cancer (MCF-7 and MDA-MB-231) as well as colon carcinoma (HT-29) cells. The most active compound 5c was slightly less active against MCF-7 cells, more active against MDA-MB-231 cells and comparable active as cisplatin against HT-29 cells. Further pharmacological investigations were performed with selected compounds on estrogen receptor (ER) binding, DNA intercalation, cyclooxygenase (COX) inhibition and antibacterial activity. The complexes were only marginally active at the DNA, ER and the COX enzymes, so these targets can be excluded to be involved in the mode of action. However, the growth of bacteria was significantly inhibited by 5c and 5f and opens a new application of this complex type.

NHC gold halide complexes derived from 4,5-diarylimidazoles: Synthesis, structural analysis, and pharmacological investigations as potential antitumor agents

Liu, Wukun,Bensdorf, Kerstin,Proetto, Maria,Abram, Ulrich,Hagenbach, Adelheid,Gust, Ronald

, p. 8605 - 8615 (2012/02/03)

A series of novel neutral NHC gold halide complexes derived from 4,5-diarylimidazoles were synthesized, characterized, and analyzed for biological effects. High growth inhibitory effects in MCF-7 and MDA-MB 231 breast cancer as well as HT-29 colon cancer cell lines depended on the presence of the C4,C5-standing aromatic rings. Methoxy groups at these rings did not change the growth inhibitory properties, while F-substituents in the ortho-position (5d) increased the activity in MCF-7 and MDA-MB 231 cells. The substituents at the nitrogen atoms and the oxidation state of the metal play a subordinate role. The most active bromo[1,3-diethyl-4,5-bis(2-fluorophenyl)-1,3- dihydro-2H-imidazol-2-ylidene]gold(I) (5d) was distinctly more active than cisplatin. All complexes caused thioredoxin reductase (TrxR) inhibition (EC 50 = 374-1505 nM) distinctly lower than auranofin (EC50 = 18.6 nM) excluding this enzyme as main target. Because of the low nuclear content, a participation of DNA interaction on the mode of action is very unlikely. The missing ER binding and the missing correlation of growth inhibition and inactivation of COX enzymes exclude these targets, too. (Figure presented)

Synthesis, structural evaluation, and estrogen receptor interaction of 4,5-Bis(4-hydroxyphenyl)imidazoles

Gust, Ronald,Keilitz, Roland,Schmidt, Kathrin,Von Rauch, Moriz

, p. 463 - 471 (2007/10/03)

4,5-Bis(4-hydroxyphenyl)imidazoles with 2,2′-H (1), 2,2′-F (2), 2,2′-Cl (3), and 2,2′6-Cl (4) substituents in the aromatic rings were synthesized by oxidation of the respective methoxy-substituted (R,S)/(S,R)-4,5-diaryl-2-imidazolines with MnO2

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 3363-51-7